ZBH Stock Recent News
ZBH LATEST HEADLINES
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance.
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
WARSAW, Ind. , Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m.
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Large Joint Devices Market Size, Share, and Trends Analysis Global 2024-2030 MedSuite Includes: Knee Replacement Market, Hip Replacement Market, and 1 more" report has been added to ResearchAndMarkets.com's offering.
Zimmer Biomet, a leader in musculoskeletal health, excels in knee and hip replacements, and surgical robots, making it a sticky choice for many orthopedic surgeons. Competitive advantages include strong surgeon loyalty, technological innovation with the ROSA® Robot, and a global consignment-based distribution model ensuring product availability. Challenges include regulatory hurdles, reliance on elective surgeries, supply chain risks, and fierce competition from companies like Stryker.
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
WARSAW, Ind. , Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior Vice President, Investor Relations, effective September 9, 2024.
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.